Browsing by Author Mitchell, Paul L.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2006Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, Paul L.; Thomson, Jacquelyn A.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAddition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity., Clinical Colorectal Cancer, vol.6,(2),2006,pp 146-151
2009Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancerChua, Wei; Dhillon, Haryana; Clark, SJ.; Goldstein, D; Iacopetta, Barry J.; Lee, CK.; Michael, Michael; Mitchell, Paul L.; Concord Clinical School: Medicine; Central Clinical School: MedicineMolecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer, British Journal of Cancer, vol.101, 6,pp 998-1004
2013A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaBrown, Christopher; Pavlakis, Nick; Stockler, Martin; Bibby, David C; Boyer, Michael; Byrne, Michael J.; Creaney, Jenette; Hughes, Brett; Kremmidiotis, Gabriel; Leske, Annabell; Millward, Michael; Mitchell, Paul L.; Nowak, Anna; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreA phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma, Lung Cancer, vol.81, 3, 2013,pp 422-427
2008Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rateJiang, Xuemin; McLachlan, Andrew; Galettis, Peter; Links, Matthew; Mitchell, Paul L.; Pharmacy; PharmacyPopulation pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate, British Journal of Clinical Pharmacology, vol.65, 3, 2008,pp 326-333
2006Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination.Clarke, Stephen; Zalcberg, John; Di Iulio, Juliana; Ellis, Andrew; et, al; Gurtler, Volker; Hicks, Rod J.; Michael, Michael; Milner, Alvin D.; Mitchell, Paul L.; Scott, Andrew; Thompson, Mick; Concord Clinical School: ANZAC Research Institute; School of Public Health: NH&MRC Clinical Trials CentreRelationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(26),2006,pp 4228-4235